Curalogic reports positive results from study of its grass allergy product  

2007.05.03
Danish biopharmaceutical company Curalogic has achieved positive results from a phase II clinical study of its product for the treatment of grass allergy
Danish biopharmaceutical company Curalogic has achieved positive results from a phase II clinical study of its product for the treatment of grass allergy. The primary objective of the GPE 02 study was to determine the maximum tolerated dose in patients with grass pollen allergy. Dr. Jörg Kleine-Tebbe of the Allergy & Asthma Center Westend in Berlin, Germany, who was involved in the trial, says:
 
"Oral administration of high doses of grass pollen extract was well tolerated by all patients in this study. The top dose of 64,000 BAU* was approximately 30 times higher than the maintenance dose with injection immunotherapy recommended in the US. The GPE 02 study is an important step in developing an oral immunotherapy grass pollen product that may provide an easy and safe alternative to standard immunotherapy."
 
Curalogic is now planning to take its product into an EU phase III study. Peter Moldt, managing director of Curalogic says: "It is important to us that we are ready to go into phase III. We have now determined how the compound is tolerated even at very high doses, and it's better tolerated than we dared dream of."
 
Approximately 51 million people in Europe and 30 million in the US suffer from grass allergy. Curalogic aims to develop a new regime for the treatment of allergy with drugs which are as efficient as injections and at the same time as easy and safe as well-known symptom-relieving drugs like antihistamines and nasal sprays. The news was reported by financial daily newspaper Børsen and on Curalogic's website.
 
* BAU is the biological potency of the product defined relative to a FDA reference standard for grass pollen extract – Ed.
 
Link > Curalogic 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×